SCHEMBL6901699

SCHEMBL6901699

CCCCOc1cn(-c2ccc3[nH]c(-c4ccc(O)cc4)nc3c2)ccc1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 1/20 0.38
ATP4B P51164 1/20 0.38
TOP1 P11387 2/20 0.37
TOP2A P11388 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HPSE Q9Y251 1/20 0.36
SCD O00767 1/20 0.36
GPR84 Q9NQS5 1/20 0.35
GUSB P08236 1/20 0.35
CHEK2 O96017 1/20 0.35
GCGR P47871 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14828462 0.91 DRD2 (0.44) ATP4AATP4BALDH1A1HPGDSMN1; SMN2
SCHEMBL17196169 0.85 CHEK2 (0.43) GUSBCHEK2
SCHEMBL2466309 0.79 NPC1 (0.45) ALDH1A1HPGDSMN1; SMN2HSD17B10GUSB
SCHEMBL2468255 0.77 NPC1 (0.47) ALDH1A1HPGDSMN1; SMN2HSD17B10GUSB
SCHEMBL2466928 0.75 COMT (0.43) ALDH1A1SMN1; SMN2HPSECHEK2
SCHEMBL14816426 0.73 COMT (0.57) ALDH1A1HPGDSMN1; SMN2SCDGUSB
SCHEMBL465476 0.68 PLG (0.56) ATP4AATP4BCHEK2HDAC3HDAC4
SCHEMBL6900917 0.68 COMT (0.55) ALDH1A1
SCHEMBL21017182 0.66 PLG (0.51) CHEK2HDAC3HDAC4HDAC1HDAC7
SCHEMBL21018408 0.66 CHEK2 (0.61) ATP4AATP4BCHEK2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9399651-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders Merck, Sharp & Dohme Corp. (US) 2016-07-26 US disclosed
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2015-10-22 US disclosed
WO-2011109254-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT ATP4A 1801/4885ATP4B 2488/4885TOP1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.